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Introduction: Elevating the availability of fatty-acids to the muscle can potentiall y 
benefit endu rance exercise performance by reducing intramuscular-glycogen utilisation. 
Digestion of triglycerides containing long-chain fatty acids (LCFAs) is slow, and fatty acids 
must pass through the carnit ine palmityl transferase (CPT) transport system to enter the 
mitochondri a, which potentially limits fat ox idation during prolonged-heavy exercise. 
Conversely, medium-cha in triglycerides (MCTs) are rapidly digested and the ir constituent 
fa tty ac ids (MCF As) by-pass the CPT transport system. Ingestion of MCFAs may therefore 
supply mitochondrial acetyl-CoA, potentiall y reducing the requirement for glycolytic fl ux 
during exercise. However, studies comparing carbohydrate (CHO) with CHO-containing 
MCF A-rich exercise supplements have revealed inconsistent results, probably because of the 
variation in gastrointesti nal (GI) distress suffered by parti cipants associated with MCT 
ingestion. 
Purpose: To investi gate whether 2-weeks of dietary adaptati on to MCF A-rich 
supplements reduces the severity of gastrointestina l (GI) distress, or increases the rate of 
MCFA oxidation during endurance exercise. A decrease in ratings of G l distress, or an 
increase in MCFA oxidation was antic ipated to lead to perfo rmance benefits. 
Method: N ine well-trained male endurance cycl ists panicipated in a double-blind, 
pseudo-randomised, tri ple-crossover protocol. Participants were 37 ± 7.26 years, 8 1.36 ± 
7.67 kg, train ing at least 8-1 0 h per week and rid ing competitively. Mean VO 2max and peak 
power output (PPO) were 4.84 ± 0.46 L·min-1 and 357.33 ± 20.55 W respecti vely. T he effects 
of a 2-week MCFA-rich d iet + 13C-enriched MCFA+CHO exercise supplement (MC-MC) on 
G I d istress, MCF A-ox idation rate and sprint perfo rmance variables were compared agai nst a 
2-week LCFA-rich diet w ith either: (a) a 13C-enriched MCFA+CHO exercise supplement 
(LC -MC), or (b) a C HO-only supplement (LC-CHO). Dietary and exercise MCFA-rich 
supplements were consumed in the form of randomised-structured triacylglycerols made with 
a 3: l molar ratio of MC- and LCF As randoml y esterified to glycerol backbones. Participants 
followed a controlled training regime whilst on the diets. 
T he perfo rmance test consisted of a 3-h ride at 50% PPO followed by 10 max imal sprints. 
At rest and every 20-min throughout the ride, participant ratings of GI and exertion sensations 
were recorded, fo llowed by external respiratory-gas analysis, collection of a breath sample fo r 
breath 13C-enrichment analysis, a venous blood sample and ingestion of a supplement. 
Ill 
S imilarly, after sprints 1, 4, 7 and 10 participants recorded their GI ratings fo llowed by a 
blood sample. 
Results: Peak MCFA-oxidation rates were 0 .3 8 g·min-1 (95% CI 0.3 1-0.47) and 0.43 
g· min-1 (0.30-0.6 1, p-value = 0.2 1) in the MC-MC and LC-MC conditions respectively, but 
there was no evidence fo r CHO sparing fo llowing MCF A adaptation. Participant ratings o f 
G I di stress decreased slightl y during exerc ise w ith 2-weeks of a diet high in MCF As relative 
to LCFAs. Ratings o f reflu x, bloatedness, nausea, and urge to vomit were, respectively, 1.34 
(0.88-3.14), 1.03 (0.74-2.27), 0.8 1 (0.62-1.69) and 0.93 (0.64-2.45) scale uni ts lower in the 
M C-MC condition relati ve to LC-MC. The attenuation in GI distress correspondc!d with a 
tendency toward increased sprint mean power, wh ich was 3.4% (± 5.9%, 0.25) higher in the 
MC-MC conditio n rela tive to LC-MC. However, sprint mean power was still lower in both 
the MC-MC (6.8% ± 2. 8%, <0 .000 1) and LC-MC ( 10.4% ± 5.5%, 0.0004) cond itions relative 
to LC-CHO. 
Mechanism covaria te a nalysis illustrated a negative effect of the GI d istress marker 
nausea on sprint perfo rmance. For every I unit increase in na usea for the MC-MC and LC-
MC conditions, sprint power decreased by 6 W (± 3.8, 0.004) relative to LC-CHO. 
Conclusion: No clear metabo li c adaptation was evident with high d ietary MCF A relative 
to LCFA. In add ition, MCFA-rich exercise supplements caused a decrement in performance 
re lative to CHO ingestion in both MC-MC and LC-MC conditions, suggesting that light-
moderate GI di stress still causes substantia l performa nce detriments. There was little 
evidence to support the ingestion o f randomised structured trig lycerides high in MCF A with 
the intenti on of enhancing endurance perfo rmance. 
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